Compositions and methods for treating hypertension
The technology described herein is directed to agents that reduce the level of oxidant-modified ET-B Cys405, Cys403, or Cys402 and the identification and use of such agents for, e.g. to treat hypertension.
1. A method of treating hypertension in a subject in need thereof, the method comprising administering to the subject an ET-B polypeptide comprising an oxidant-resistant mutation at Cys405, Cys403, or Cys402.
2. The method of claim 1 , wherein the subject is in need of treatment for a condition selected from the group consisting of:
systemic hypertension and pulmonary arterial hypertension.
3. The method of claim 1 , wherein the oxidant-resistant mutation is the substitution of a cysteine with an alanine, valine, leucine, or isoleucine.
4. The method of claim 1 , wherein the oxidant-resistant mutation at Cys405 is selected from: Cys405Ala; Cys405Val; Cys405Leu; and Cys405Ile.
5. A method of treating hypertension in a subject in need thereof, the method comprising administering to the subject a nucleic acid encoding an ET-B polypeptide comprising an oxidant-resistant mutation at Cys405, Cys403, or Cys402.
6. The method of claim 5 , wherein the oxidant-resistant mutation is the substitution of a cysteine with an alanine, valine, leucine, or isoleucine.
7. The method of claim 5 , wherein the oxidant-resistant mutation at Cys405 is selected from: Cys405Ala; Cys405Val; Cys405Leu; and Cys405Ile.
8. The method of claim 5 , wherein the subject is in need of treatment for a condition selected from the group consisting of:
systemic hypertension and pulmonary arterial hypertension.